Virtus Biotech Clinical Trials ETF
18 hedge funds and large institutions have $14.7M invested in Virtus Biotech Clinical Trials ETF in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
5% less funds holding
Funds holding: 19 → 18 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
22.68% less ownership
Funds ownership: 54.72% → 32.04% (-23%)
65% less capital invested
Capital invested by funds: $42.1M → $14.7M (-$27.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$622K |
| 2 |
CCP
Cardan Capital Partners
Denver,
Colorado
|
+$443K |
| 3 |
Jane Street
New York
|
+$313K |
| 4 |
AWM
AE Wealth Management
Topeka,
Kansas
|
+$256K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$196K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
-$16.6M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$6.75M |
| 3 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$4.87M |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$797K |
| 5 |
VF
Virtu Financial
New York
|
-$369K |
BBC Hedge Fund Activity: Q3 2018 in Review
18 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q3 2018, worth a combined $14.7M — down 65% from $42.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BBC and 4 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $622K. The largest seller was Niemann Capital Management, exiting entirely with an estimated $16.6M sold.
- 18 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q3 2018, down from 19 in Q2 2018.
- Funds reported $14.7M of Virtus Biotech Clinical Trials ETF stock for Q3 2018, down 65% quarter-over-quarter.
- 4 funds opened new Virtus Biotech Clinical Trials ETF positions in Q3 2018 and 5 closed out, a net change of -1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q3 2018 was Citadel Advisors, an estimated $622K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q3 2018 was Niemann Capital Management, an estimated $16.6M sold.
Based on aggregated 13F filings for Q3 2018.